10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid | 905303-12-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid
• 英文别名: 4-(9-Carboxynonyloxy)benzoic acid tert-butyl ester；10-[4-[(2-methylpropan-2-yl)oxycarbonyl]phenoxy]decanoic acid
• CAS: 905303-12-0
• 化学式: C₂₁H₃₂O₅
• 分子量: 364.482
• InChiKey: ZTJJDVCSOPGGST-UHFFFAOYSA-N

物化性质

• 沸点：
  503.0±20.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid 在 N,N-二异丙基乙胺 作用下， 生成
  参考文献：
  名称：

  [EN] IMMUNOMODULATORS
  [FR] IMMUNOMODULATEURS

  摘要：

  The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

  公开号：

  WO2023069994A1
• 作为产物：
  描述：

  4-(9-methoxycarbonylnonyloxy)benzoic acid tert-butyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 16.0h， 以95%的产率得到10-(4-(tert-butoxycarbonyl)phenoxy)decanoic acid
  参考文献：
  名称：

  WO2007/128817

  摘要：

  公开号：

文献信息

• [EN] FGF21 DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE FGF21 ET UTILISATIONS DE CEUX-CI
  申请人：NOVO NORDISK AS

  公开号：WO2016102562A1

  公开（公告）日：2016-06-30

  The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.

  该发明涉及一种FGF21蛋白的衍生物，在该衍生物中，在与成熟人类FGF21的位置167、169、170、171、172、173、174、175以及特别是位置180或位置181相对应的位置上具有一个半胱氨酸残基，并且该半胱氨酸上连接有一个侧链。该发明的FGF21衍生物对FGF受体表现出高效性。该发明还涉及包括这些FGF21衍生物和药用可接受的赋形剂的制药组合物，以及FGF21衍生物的医药用途。
• [EN] PHARMACEUTICAL COMPOSITIONS OF FGF21 DERIVATIVES AND USES THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE DÉRIVÉS DE FGF21 ET LEURS UTILISATIONS
  申请人：NOVO NORDISK AS

  公开号：WO2017220706A1

  公开（公告）日：2017-12-28

  The present invention relates to pharmaceutical compositions. In particular compositions comprising derivatives of analogues of FGF21, more in particular to analogues of FGF21 having a side chain attached to a cysteine in the C-terminal part of FGF21. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of such compositions.

  本发明涉及制药组合物。具体而言，涉及包含FGF21类似物衍生物的组合物，更具体地说是具有连接到FGF21 C末端的半胱氨酸的FGF21类似物。该发明还涉及包含这种FGF21衍生物和药用可接受的辅料的制药组合物，以及这种组合物的医药用途。
• MIC-1 Compounds and Uses Thereof
  申请人：Novo Nordisk A/S

  公开号：US20180339057A1

  公开（公告）日：2018-11-29

  The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

  这项发明涉及MIC-1化合物。更具体地，它涉及包含具有N-末端氨基酸延伸和一个前导物的MIC-1多肽的化合物，其中氨基酸延伸包括3到36个氨基酸残基，而MIC-1多肽和N-末端氨基酸延伸共同具有计算的等电点低于6.5。该发明的化合物具有MIC-1活性。该发明还涉及包含这种化合物和药用可接受的赋形剂的药物组合物，以及这些化合物的医药用途。
• GLP-1 PRODRUGS
  申请人：Novo Nordisk A/S

  公开号：US20150045281A1

  公开（公告）日：2015-02-12

  The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analogue thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products. The invention furthermore relates to a method of achieving release in vivo of an active and stabilised GLP-1 parent drug of the general formula II: (HOHis)-(GLP-1 peptide), by administering a GLP-1 prodrug; as well as to such GLP-1 prodrug, and such GLP-1 parent drug, respectively, for use as a medicament, in particular for use in the treatment and/or prevention of all forms of diabetes and related diseases. The prodrug may be used to alter the PK and/or absorption profile of the drug, for example to a desirable bell-shaped curve. The parent drug has a good biological activity, and is stabilised against degradation by DPP-IV.

  该发明涉及通式I的GLP-1前药：R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1肽)（通式I），其中GLP-1肽是GLP-1(8-37)（序列ID号：1）或其类似物，与GLP-1(8-37)相比最多具有九个氨基酸变化，R1是较低的烷基，(NHXaa1)是一种氨基酸，Xaa2是一种氨基酸，(OHis)是咪唑乳酸的基团；或者是该前药的药用盐、酰胺或酯。该发明还涉及通式II的特定GLP-1母药：(HOHis)-(GLP-1肽)（通式II），以及特定的中间产物。此外，该发明还涉及通过给予GLP-1前药来在体内释放通式II的活性和稳定的GLP-1母药的方法：(HOHis)-(GLP-1肽)，以及用作药物的该GLP-1前药和该GLP-1母药，特别是用于治疗和/或预防所有形式的糖尿病和相关疾病。该前药可用于改变药物的PK和/或吸收特性，例如使其呈现理想的钟形曲线。母药具有良好的生物活性，并且受到DPP-IV的降解稳定性的保护。
• Double-acylated GLP-1 derivatives
  申请人：Novo Nordisk A/S

  公开号：US10000542B2

  公开（公告）日：2018-06-19

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

  本发明涉及一种GLP-1类似物的衍生物，该类似物包括第一个K残基和第二个K残基，分别位于与GLP-1（7-37）（SEQ ID NO：1）的位置26和37相对应的位置上，并且与GLP-1（7-37）相比最多有八个氨基酸变化；该衍生物包括通过连接剂连接到所述第一个和第二个K残基上的两个延长基团，其中所述延长基团选自Chem.1：HOOC-（CH2）x-CO-*和Chem.2：HOOC-C6H4-O-（CH2）y-CO-*，其中x为8-16的整数范围内的整数，y为6-13的整数范围内的整数；连接剂包括Chem.3：* -NH-（CH2）q-CH [（CH2）w-NR1R2] -CO- *，它在其CO- *端连接到GLP-1类似物的第一个或第二个K残基的epsilon氨基基团上，其中q为0-5的整数范围内的整数，R1和R2独立地表示* -H或* -CH3，w为0-5的整数范围内的整数；或其药学上可接受的盐，酰胺或酯。本发明还涉及其在治疗和/或预防所有形式的糖尿病和相关疾病中的药物应用，以及相应的新型肽和连接剂中间体。这些衍生物具有高效、稳定、持久和适合口服给药的特点。